These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28431670)

  • 1. Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure.
    Joubert M; Reznik Y
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S34-2S38. PubMed ID: 28431670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
    Brunton SA; Wysham CH
    Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
    Castellana M; Cignarelli A; Brescia F; Laviola L; Giorgino F
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3082. PubMed ID: 30270567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
    Lu JM
    Adv Ther; 2019 Apr; 36(4):798-805. PubMed ID: 30859500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Leiter LA; Nauck MA
    Exp Clin Endocrinol Diabetes; 2017 Jul; 125(7):419-435. PubMed ID: 28724168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.
    Cimmaruta D; Maiorino MI; Scavone C; Sportiello L; Rossi F; Giugliano D; Esposito K; Capuano A
    Expert Opin Drug Saf; 2016 Dec; 15(sup2):77-83. PubMed ID: 27875915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association.
    Cariou B
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S28-6S35. PubMed ID: 26774017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
    Lovshin JA
    Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
    Goldenberg RM; Berard L
    Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study.
    Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
    Diabetes Obes Metab; 2019 Nov; 21(11):2542-2552. PubMed ID: 31364233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
    Busch RS; Kane MP
    Postgrad Med; 2017 Sep; 129(7):686-697. PubMed ID: 28657399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice.
    Artigas CF; Stokes V; Tan GD; Theodorakis MJ
    Expert Opin Pharmacother; 2015; 16(10):1417-21. PubMed ID: 26077113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
    Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
    Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M; Miossec P; Larsen BD; Werner U; Knop FK
    Expert Opin Drug Discov; 2014 Oct; 9(10):1223-51. PubMed ID: 25119443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of new GLP-1 receptor agonists for type 2 diabetes.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016; 25(2):145-58. PubMed ID: 26587691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GLP-1 receptor agonists in NAFLD.
    Petit JM; Vergès B
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S28-2S33. PubMed ID: 28431668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.